Palvella Reports Q2 2026 Results: $250.6M Cash, NDA Submission Underway, Pipeline Advances

summarizeSummary

Palvella Therapeutics reported Q2 2026 financial results with $250.6 million in cash, submitted the first module of its rolling NDA for QTORIN™ rapamycin, and outlined multiple pipeline milestones, including Phase 3 initiation for cutaneous VMs and Phase 2 starts for DSAP and angiokeratomas.

check_boxKey Events · Earnings and Guidance · PVLA

• Q2 2026 Financial Results

  Net loss of $21.9 million ($1.52/share) on increased R&D ($12.5M) and G&A ($8.9M) spending. Cash, equivalents, and short-term investments totaled $250.6 million as of June 30, 2026.

• Rolling NDA Submission Initiated

  First module of the rolling NDA for QTORIN™ rapamycin in microcystic LMs submitted to FDA; completion on track for 2H 2026, with potential U.S. launch in 1H 2027.

• Pipeline Advancement

  Phase 3 trial for cutaneous VMs planned for Q4 2026; Phase 2 trials for DSAP and angiokeratomas expected to start in 2H 2026, with topline LOTU data in 2H 2027.

• Commercial Preparation

  Veteran commercial leadership recruited; sales force planned at ~40 reps to support potential 2027 launch of QTORIN™ rapamycin.

auto_awesomeAnalysis · PVLA · Life Sciences

Palvella's Q2 update shows a strong cash position of $250.6 million, funding operations through multiple near-term catalysts. The first module of the rolling NDA for QTORIN™ rapamycin in microcystic LMs has been submitted, with completion on track for the second half of 2026 and a potential U.S. launch in the first half of 2027. The company is also advancing Phase 3 for cutaneous VMs and Phase 2 trials for angiokeratomas and DSAP, with data readouts expected in 2027. Increased R&D and G&A spending reflects pre-commercial buildout, including a planned ~40-person sales force. The net loss widened to $21.9 million, but the balance sheet provides ample runway.